Lyell Immunopharma, Inc. (LYEL) stock
LYELNasdaqPharmaceutical PreparationsFiscal year ends December 31
$13.67−0.98 (-6.69%)
Close on Nov 17, 2026Market cap $334.99MP/E –Yield –
Lyell Immunopharma r&d expenses
Research and development expenses are spending on new products and technology.
Lyell Immunopharma's R&D Expenses for the twelve months ending Jun 30, 2026 was $156.50M, down 6.0% year over year. For fiscal 2025 it was $158.68M, down 7.5% from the year before. The highest annual figure on record is $182.95M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $158.68M | -7.5% |
| FY2024 | Dec 31, 2024 | $171.60M | -6.2% |
| FY2023 | Dec 31, 2023 | $182.95M | +14.9% |
| FY2022 | Dec 31, 2022 | $159.19M | +14.8% |
| FY2021 | Dec 31, 2021 | $138.69M | -23.9% |
| FY2020 | Dec 31, 2020 | $182.24M | +186.6% |
| FY2019 | Dec 31, 2019 | $63.60M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $39.52M | +13.4% |
| Q1 FY2026 | Mar 31, 2026 | $36.60M | -15.8% |
| Q4 FY2025 | Dec 31, 2025 | $52.20M | +7.3% |
| Q3 FY2025 | Sep 30, 2025 | $28.17M | -28.7% |
| Q2 FY2025 | Jun 30, 2025 | $34.86M | -13.4% |
| Q1 FY2025 | Mar 31, 2025 | $43.45M | +0.6% |
| Q4 FY2024 | Dec 31, 2024 | $48.67M | +3.6% |
| Q3 FY2024 | Sep 30, 2024 | $39.50M | -9.9% |
| Q2 FY2024 | Jun 30, 2024 | $40.26M | -15.2% |
| Q1 FY2024 | Mar 31, 2024 | $43.17M | -3.3% |
| Q4 FY2023 | Dec 31, 2023 | $47.00M | +23.6% |
| Q3 FY2023 | Sep 30, 2023 | $43.85M | +5.4% |
| Q2 FY2023 | Jun 30, 2023 | $47.47M | +8.6% |
| Q1 FY2023 | Mar 31, 2023 | $44.63M | +24.6% |
| Q4 FY2022 | Dec 31, 2022 | $38.03M | +97.2% |
| Q3 FY2022 | Sep 30, 2022 | $41.61M | +32.4% |
| Q2 FY2022 | Jun 30, 2022 | $43.72M | -5.9% |
| Q1 FY2022 | Mar 31, 2022 | $35.83M | -13.7% |
| Q4 FY2021 | Dec 31, 2021 | $19.29M | -45.0% |
| Q3 FY2021 | Sep 30, 2021 | $31.43M | +28.3% |
| Q2 FY2021 | Jun 30, 2021 | $46.45M | -52.2% |
| Q1 FY2021 | Mar 31, 2021 | $41.53M | – |
| Q4 FY2020 | Dec 31, 2020 | $35.09M | – |
| Q3 FY2020 | Sep 30, 2020 | $24.50M | – |
| Q2 FY2020 | Jun 30, 2020 | $97.15M | – |
See a number that looks wrong?